As there is robust evidence supporting a greater efficacy of the combined PD-1/CTLA-4 blockade over the two monotherapies in advanced solid cancer (18), the possible inclusion of patients with PC in the NCT02834013 trial is giving rise to great expectations. The gene discussed is CTLA4; the disease is pachyonychia congenita.